FDA clears St. Jude's combined OCT, FFR system

St. Jude Medical has received FDA clearance for its Ilumien system, a diagnostic technology that combines optical coherence tomography (OCT) and fractional flow reserve (FFR) technologies on one platform.

The combined system offers physicians physiological and anatomical insight for the diagnosis and treatment of coronary artery disease.

The Ilumien system features the St. Jude Medical PressureWire Aeris, a wireless interventional tool that measures FFR to evaluate the severity of blood flow blockages in the coronary arteries, and St. Jude's C7-XR OCT diagnostic imaging technology with Extreme Resolution, an intravascular imaging technology that allows physicians to visualize and measure vessel characteristics. Combined, the two technologies may assist physicians in identifying culprit lesions responsible for ischemia, and also provide physicians with measurements of lesion dimensions, as well as vessel size and structure, according to the St. Paul, Minn.-based company.

St. Jude's Ilumien system features the Wi-Box, a device that enables the Ilumien system to receive wireless aortic pressure readings.

The Ilumien system was launched in Europe earlier this year.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.